Search Results - "Cassaday, Ryan D."

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy by Shadman, Mazyar, Gauthier, Jordan, Hay, Kevin A., Voutsinas, Jenna M., Milano, Filippo, Li, Ang, Hirayama, Alexandre V., Sorror, Mohamed L., Cherian, Sindhu, Chen, Xueyan, Cassaday, Ryan D., Till, Brian G., Gopal, Ajay K., Sandmaier, Brenda M., Maloney, David G., Turtle, Cameron J.

“…Allogeneic hematopoietic cell transplantation (allo-HCT) is offered to selected patients after chimeric antigen receptor–modified T-cell (CAR-T) therapy…”
Get full text

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms by Halpern, Anna B, Othus, Megan, Huebner, Emily M, Scott, Bart L, Hendrie, Paul C, Percival, Mary-Elizabeth M, Becker, Pamela S, Smith, Heather A, Oehler, Vivian G, Orozco, Johnnie J, Cassaday, Ryan D, Gardner, Kelda M, Chen, Tara L, Buckley, Sarah A, Orlowski, Kaysey F, Anwar, Asma, Estey, Elihu H, Walter, Roland B

Get full text

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? by Fingrut, Warren, Davis, Wendy, McGinnis, Eric, Dallas, Karen, Ramadan, Khaled, Merkeley, Hayley, Leitch, Heather, Abou Mourad, Yasser, Cassaday, Ryan D, Ross, Camilla, Léger, Chantal

“…Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22…”
Get full text

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes by Saygin, Caner, Kishtagari, Ashwin, Cassaday, Ryan D., Reizine, Natalie, Yurkiewicz, Ilana, Liedtke, Michaela, Stock, Wendy, Larson, Richard A., Levine, Ross L., Tallman, Martin S., Park, Jae H., Kerr, Cassandra, Przychodzen, Bartlomiej, Sekeres, Mikkael A., Kalaycio, Matt E., Carraway, Hetty E., Hamilton, Betty K., Sobecks, Ronald, Gerds, Aaron, Mukherjee, Sudipto, Nazha, Aziz, Maciejewski, Jaroslaw P., Advani, Anjali S.

“…Patients with therapy-related acute lymphoblastic leukemia (t-ALL) represent a small subset of acute lymphoblastic leukemia (ALL) patients who received…”
Get full text

Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes by Cassaday, Ryan D.

“…Asparaginase in various forms is a standard part of the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. However, its use is more…”
Get full text

Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 by Shah, Bijal D, Cassaday, Ryan D, Park, Jae H, Houot, Roch, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick J, Jeyakumar, Deepa, Mao, Daqin, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C, Damico Khalid, Rita, Ghobadia, Armin

“…Background Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the USA for adults with…”
Get full text

How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia by Kopmar, Noam E., Cassaday, Ryan D.

“…[Display omitted] The central nervous system (CNS) is the most important site of extramedullary disease in adults with acute lymphoblastic leukemia (ALL)…”
Get full text

When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia by Cassaday, Ryan D.

“…A randomized controlled trial of blinatumomab for the treatment of patients with Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia is…”
Get full text

Posterior reversible encephalopathy syndrome associated with dose-adjusted EPOCH chemotherapy by Floeter, Abby E., PharmD, Patel, Amila, PharmD, Tran, Melinda, PharmD, Chamberlain, Marc C., MD, Hendrie, Paul C., MD, PhD, Gopal, Ajay K., MD, Cassaday, Ryan D., MD

“…Abstract Introduction The purpose of our study was to identify key risk factors for the development of posterior reversible encephalopathy syndrome (PRES)…”
Get full text

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia by Marks, David I., Kebriaei, Partow, Stelljes, Matthias, Gökbuget, Nicola, Kantarjian, Hagop, Advani, Anjali S., Merchant, Akil, Stock, Wendy, Cassaday, Ryan D., Wang, Tao, Zhang, Hui, Loberiza, Fausto, Vandendries, Erik, DeAngelo, Daniel J.

“…•Salvage with inotuzumab can provide a bridge to transplant in relapsed/refractory acute lymphoblastic leukemia.•A high chance of achieving minimal residual…”
Get full text

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy by DeFilipp, Zachariah, Advani, Anjali S., Bachanova, Veronika, Cassaday, Ryan D., Deangelo, Daniel J., Kebriaei, Partow, Rowe, Jacob M., Seftel, Matthew D., Stock, Wendy, Tallman, Martin S., Fanning, Suzanne, Inamoto, Yoshihiro, Kansagra, Ankit, Johnston, Laura, Nagler, Arnon, Sauter, Craig S., Savani, Bipin N., Perales, Miguel-Angel, Carpenter, Paul A., Larson, Richard A., Weisdorf, Daniel

“…The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic…”
Get full text

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study by Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Feng, Chaoling, Dong, Jinghui, Shen, Tong, Milletti, Francesca, Rossi, John M, Vezan, Remus, Masouleh, Behzad Kharabi, Houot, Roch

“…Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-SCT) consolidation, outcomes in adult patients with relapsed or refractory…”
Get full text

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy by Hay, Kevin A., Gauthier, Jordan, Hirayama, Alexandre V., Voutsinas, Jenna M., Wu, Qian, Li, Daniel, Gooley, Ted A., Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Schoch, Gary, Chapuis, Aude G., Till, Brian G., Kiem, Hans-Peter, Ramos, Jorge D., Shadman, Mazyar, Cassaday, Ryan D., Acharya, Utkarsh H., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease–negative…”
Get full text

A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients by CASSADAY, Ryan D, SONDEL, Paul M, HANK, Jacquelyn A, MAHVI, David M, ALBERTINI, Mark R, KING, David M, MACKLIN, Michael D, GAN, Jacek, WARNER, Tom F, ZULEGER, Cindy L, BRIDGES, Alan J, SCHALCH, Heidi G, KYUNG MANN KIM

“…Purpose: We examined in vivo particle-mediated epidermal delivery (PMED) of cDNAs for gp100 and granulocyte macrophage colony-stimulating factor (GM-CSF) into…”
Get full text

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells by Hirayama, Alexandre V., Gauthier, Jordan, Hay, Kevin A., Voutsinas, Jenna M., Wu, Qian, Gooley, Ted, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Acharya, Utkarsh H., Cassaday, Ryan D., Chapuis, Aude G., Dhawale, Tejaswini M., Hendrie, Paul C., Kiem, Hans-Peter, Lynch, Ryan C., Ramos, Jorge, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma…”
Get full text

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review by Cassaday, Ryan D., Gopal, Ajay, Fromm, Jonathan R., Potts, D. Alan

“…Non-Hodgkin lymphomas (NHL) are a heterogeneous group of hematologic malignancies typically treated with multiagent chemotherapy. Rarely, spontaneous…”
Get full text

Allogeneic hematopoietic cell transplantation in mantle cell lymphoma by Cassaday, Ryan D., MD, Gopal, Ajay K., MD

“…Mantle cell lymphoma (MCL) is a high-risk non-Hodgkin lymphoma that is considered incurable with standard chemotherapy. While autologous hematopoietic cell…”
Get full text

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies by Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

“…CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell…”
Get full text

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results by Shah, Bijal D., Bishop, Michael R., Oluwole, Olalekan O., Logan, Aaron C., Baer, Maria R., Donnellan, William B., O'Dwyer, Kristen M., Holmes, Houston, Arellano, Martha L., Ghobadi, Armin, Pagel, John M., Lin, Yi, Cassaday, Ryan D., Park, Jae H., Abedi, Mehrdad, Castro, Januario E., DeAngelo, Daniel J., Malone, Adriana K., Mawad, Raya, Schiller, Gary J., Rossi, John M., Bot, Adrian, Shen, Tong, Goyal, Lovely, Jain, Rajul K., Vezan, Remus, Wierda, William G.

“…ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R)…”
Get full text

Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy by Smith, Stephen D., Till, Brian G., Shadman, Mazyar S., Lynch, Ryan C., Cowan, Andrew J., Wu, Qian V., Voutsinas, Jenna, Rasmussen, Heather A., Blue, Katherine, Ujjani, Chaitra S., Shustov, Andrei, Cassaday, Ryan D., Fromm, Jonathan R., Gopal, Ajay K.

“…Summary Tumor programmed death‐ligand 1 (PD‐L1) expression in diffuse large B‐cell lymphoma (DLBCL) is associated with inferior outcomes. The first‐line…”
Get full text